Clinical reluctance is often assumed to be what keeps these drugs from people who want them. This survey of Swedish primary care physicians (n = 163 analyzed, from 190 responses) suggests it is not, at least where it was conducted [1]. What patients say about the care they receive alongside is in what patients said when asked.
Agreement was close to unanimous. Ninety-eight percent of responding physicians agreed the drugs are effective for obesity, and 91% expected them to be important to obesity treatment going forward. The obstacles they named were not about efficacy or safety at all: supply shortages at 86% and what patients have to pay at 69%.
The supply figure also needs a date attached. Fieldwork ran in October 2024, during the documented shortage period, and the authors qualify it as reflecting availability at the time of the survey. Reporting 86% today without that timestamp would describe a bottleneck that has since substantially changed — and the market that filled the gap while it lasted is the subject of what the secret-shopper study found.
The other barrier travels better. Patient co-payment blocking prescriptions in a publicly funded system is a version of the same problem that dominates a cash market, and it sits beside the coverage findings in covered and still not treated and who the price filtered out. Across very different health systems, the thing standing between people and these drugs keeps coming back as money rather than medicine.
Sweden is not the United States, and the transfer is limited. Prescribing norms, co-payment structures and what a primary care physician is expected to manage all differ. What does carry is the direction: where doctors were asked directly, they described themselves as willing and constrained, which reframes the question a buyer should ask a seller from “will someone prescribe this” to “what am I actually paying for”.